Barclays analyst Carter Gould maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $27.18.
According to TipRanks, Gould is a 4-star analyst with an average return of 7.9% and a 53.88% success rate. Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, AbbVie, and Biogen.
In addition to Barclays, Pfizer also received a Hold from J.P. Morgan’s Chris Schott in a report issued yesterday. However, today, Goldman Sachs maintained a Buy rating on Pfizer (NYSE: PFE).
The company has a one-year high of $38.80 and a one-year low of $25.20. Currently, Pfizer has an average volume of 40.26M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer (PFE) Company Description:
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- PFE Earnings: Pfizer Rises After Smashing Q1 Estimates
- Options Volatility and Implied Earnings Moves Today, May 01, 2024
- Notable companies reporting before tomorrow’s open
- Longboard initiated with an Outperform at Baird on ‘best-in-class potential
- Pfizer call volume above normal and directionally bullish
